Da An Gene Co Ltd of Sun Yat-Sen University - Asset Resilience Ratio
Da An Gene Co Ltd of Sun Yat-Sen University (002030) has an Asset Resilience Ratio of 4.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Da An Gene Co Ltd of Sun Yat-Sen Univers balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Da An Gene Co Ltd of Sun Yat-Sen University's Asset Resilience Ratio has changed over time. See Da An Gene Co Ltd of Sun Yat-Sen Univers shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Da An Gene Co Ltd of Sun Yat-Sen University's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002030 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥396.00 Million | 4.35% |
| Total Liquid Assets | CN¥396.00 Million | 4.35% |
Asset Resilience Insights
- Limited Liquidity: Da An Gene Co Ltd of Sun Yat-Sen University maintains only 4.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Da An Gene Co Ltd of Sun Yat-Sen University Industry Peers by Asset Resilience Ratio
Compare Da An Gene Co Ltd of Sun Yat-Sen University's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Da An Gene Co Ltd of Sun Yat-Sen University (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Da An Gene Co Ltd of Sun Yat-Sen University.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.66% | CN¥63.00 Million ≈ $9.22 Million |
CN¥9.58 Billion ≈ $1.40 Billion |
-12.05pp |
| 2023-12-31 | 12.71% | CN¥1.40 Billion ≈ $204.90 Million |
CN¥11.02 Billion ≈ $1.61 Billion |
+9.45pp |
| 2022-12-31 | 3.26% | CN¥480.90 Million ≈ $70.37 Million |
CN¥14.76 Billion ≈ $2.16 Billion |
-0.42pp |
| 2021-12-31 | 3.68% | CN¥380.01 Million ≈ $55.61 Million |
CN¥10.34 Billion ≈ $1.51 Billion |
-9.58pp |
| 2020-12-31 | 13.25% | CN¥888.00 Million ≈ $129.94 Million |
CN¥6.70 Billion ≈ $980.42 Million |
+12.12pp |
| 2019-12-31 | 1.13% | CN¥40.24 Million ≈ $5.89 Million |
CN¥3.56 Billion ≈ $521.18 Million |
-22.70pp |
| 2018-12-31 | 23.83% | CN¥873.04 Million ≈ $127.75 Million |
CN¥3.66 Billion ≈ $536.06 Million |
+25.80pp |
| 2017-12-31 | -1.97% | CN¥-91.30 Million ≈ $-13.36 Million |
CN¥4.64 Billion ≈ $679.24 Million |
-2.18pp |
| 2016-12-31 | 0.22% | CN¥9.00 Million ≈ $1.32 Million |
CN¥4.14 Billion ≈ $605.76 Million |
-1.22pp |
| 2015-12-31 | 1.43% | CN¥43.60 Million ≈ $6.38 Million |
CN¥3.04 Billion ≈ $445.10 Million |
-- |
About Da An Gene Co Ltd of Sun Yat-Sen University
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coro… Read more